A. Blackrock Neurotech: The Utah Array and Nine Years of Long-Term Implant Records

It was an event at the White House. A young man in a wheelchair waited for President Barack Obama. Nathan Copeland. A car accident ten years earlier had left him completely paralyzed below the neck. When the president walked over and held out his fist, Copeland moved a robotic arm instead of his own paralyzed hand and bumped fists with him. What came next was the real surprise. Copeland felt the texture of the president's skin through the robotic fingertips, directly in his own brain. Tactile information collected by the machine had been converted into electrical signals and transmitted to his sensory cortex. It was the first moment in human history that a machine's sense of touch was fed straight into a human brain.

The force behind this miracle was not Elon Musk's Neuralink. It was Blackrock Neurotech, a company that had been quietly paving the way for more than twenty years from a lab in Salt Lake City. While Neuralink captured public attention on a flashy stage, Blackrock had already built a massive fortress of clinical data accumulated over decades.

Blackrock's core weapon is a small chip called the Utah Array. Designed in 1989 by Professor Richard Normann at the University of Utah, the device measures just four millimeters on each side. Smaller than a shirt button. Under a microscope, 96 to 128 silicon needles rise in tight rows like the teeth of a comb, resembling a miniature bed of nails. These needles penetrate about 1.5 millimeters into the brain's cortex, capturing the electrical signals that neurons fire from the closest possible range. It is like pressing your ear right up against the brain's whisper.

There is a reason the Utah Array became the standard in BCI research. Signal quality. Placing electrodes on the scalp with EEG is like listening to a concert from outside the venue. The sound fades as it passes through walls and air. The Utah Array, by contrast, is like sitting in the front row. You can pick out individual instruments. That means it can directly record the firing of individual neurons, known as spikes. This crisp signal is what makes precise decoding possible. Controlling a robotic arm with finesse, typing on a keyboard with thought alone, restoring lost touch sensation; all of it starts with the quality of that signal.

Blackrock Neurotech's most powerful asset is trust proven by time. In the medical world, and especially in brain-related technology, the word 'cutting-edge' often means the same thing as 'unverified.' Blackrock's system, on the other hand, has demonstrated its safety for over twenty years through the BrainGate clinical trials, which began in 2004. According to the company, out of more than 35 patients worldwide who have received implanted BCIs,

31 used Blackrock technology. The accumulated human implant data exceeds 30,000 days. This is territory no startup can easily catch up to.

There is a number: nine years. That is how long Blackrock's Utah Array functioned normally inside one patient's brain. The brain does not welcome foreign objects. The immune system identifies the chip as an intruder and wraps it in scar tissue. In an environment that is hot, humid, and saturated with salt, electronic devices corrode easily. Surviving nearly a decade in such hostile terrain borders on an engineering miracle. According to a study published in July 2025, analysis of 20 Utah Arrays from 14 patients in the BrainGate clinical trials showed that an average of 35.6 percent of electrodes successfully recorded neural spike signals, and signal quality degraded by only 7 percent over a period averaging 7.6 years.

The limitations, of course, are clear. The Utah Array is made of rigid silicon. Each time the brain shifts slightly inside the skull, the device can cause small injuries to surrounding tissue. Over time, scar tissue forms around the electrodes and signal quality can decline. The traditional system also required a wired connection through a metal port protruding from the head. This device, called a pedestal, raises the risk of infection and restricts the patient's movement. When the research team went home for the day, the patient had to surrender their magical abilities and return to silence.

Blackrock is preparing for change. In late 2022, the company unveiled a next-generation system called Neuralace. The device targets more than 10,000 channels and features a thin, flexible structure designed to conform to the brain's contours. It was a direct challenge to Neuralink's N1 chip. In April 2024, cryptocurrency firm Tether invested 200 million dollars in Blackrock and became its largest shareholder. The company was valued at roughly 350 million dollars. With this funding, Blackrock is pushing to commercialize MoveAgain, a fully implantable wireless BCI system. The goal is a future where patients can freely use the device at home.

Blackrock's philosophy differs sharply from Neuralink's. While Musk dreams of tens of thousands of channels covering the entire brain and merging with AI, Blackrock focuses on practical tools a patient could use tomorrow. Co-founder Marcus Gerhardt once put it this way: "We're not writing science fiction. We're writing prescriptions." Not turning humans into transcendent beings, but restoring lost function so people can enjoy ordinary life again. Eating, drinking, feeling the touch of someone they love. The innovation Blackrock pursues is grounded in recovering the most basic elements of being human.

If Neuralink is a revolutionary army sweeping in like a storm, Blackrock Neurotech is a steadfast lord who has defended the territory for years. No one can deny that every innovation in BCI stands on the road Blackrock paved over the past two decades. The question is whether the legacy of the past alone can secure the future. What choices must an established power make when facing Silicon Valley's speed and capital? That answer is still being written.

B. Precision Neuroscience: Layer 7, the Ultra-Thin Film on the Brain's Surface

It was the spring of 2023, inside a neurosurgery operating room in New York. Dr. Benjamin Rapoport did not cut a large opening in the patient's skull. Instead, he made a micro-slit less than one millimeter wide. Through that slit, he slid in a thin yellow film, as if slipping a letter into an envelope. The film glided over the wrinkled surface of the brain. Its thickness was one-fifth the width of a human hair. This was the first human implantation of the Layer 7 cortical interface.

Rapoport is not just a doctor. He was one of the eight founding members who started Neuralink alongside Elon Musk. Trained in electrical engineering at MIT and neurosurgery at Harvard Medical School, he was a rare talent who spoke both the language of technology and the language of medicine. But he left Neuralink. The reason was a philosophical difference over safety. The Neuralink approach, where electrodes pierce brain tissue, inevitably causes microscopic brain damage. Rapoport adopted the first line of the Hippocratic oath as the first principle of brain engineering: above all, do no harm to the patient.

His solution was to cover the brain rather than pierce it. In 2021 he founded Precision Neuroscience and developed an ultra-thin electrode film that adheres to the brain's surface. The cerebral cortex is made up of six cell layers. Precision wanted its electrode to wrap gently around the brain's surface like a seventh layer instead of penetrating it. That is why they named it Layer 7.

Layer 7's technical innovations come down to a few key points. First, it is ultra-thin. Made from a flexible material called polyimide, the film is one-fifth the thickness of a human hair. Thinness is not just an aesthetic choice. When an electrode placed on the brain's surface is thick and stiff, breathing, pulsation, and subtle postural shifts create friction and pressure. That leads to inflammation and damage. A thin, flexible film follows the brain's contours naturally and minimizes that burden.

Second, high resolution. This small film packs 1,024 micro-electrodes. That channel count matches Neuralink's N1 chip. With far greater density than traditional brain-surface electrodes known as ECoG grids, it can map the brain's electrical activity like a high-resolution image. Precision also unveiled a next-generation version with 4,096 electrodes in 2024.

Third, the micro-slit surgical method. Where Neuralink must drill a coin-sized hole in the skull and Blackrock must pierce brain tissue, Precision makes only a tiny slit in the skull. Through that slit, the film slides in the way you slip a sheet of paper into an envelope. No brain tissue is damaged in the process.

Fourth, reversibility. This is the point Rapoport emphasizes most. Electrodes that are driven into the brain carry a significant risk of tissue damage when removed. Layer 7, resting on the brain's surface, can be gently pulled out. The brain tissue remains intact. When technology

is upgraded or a problem arises, being able to tell a patient 'you can have it removed whenever you want' lowers an enormous psychological barrier in clinical practice.

On March 30, 2025, Precision Neuroscience received 510(k) clearance from the FDA. The device, designated Layer 7-T, was approved for implant use of up to 30 days. The company stated this was the first full regulatory clearance received by any company developing a next-generation wireless BCI. With this approval, Precision can now sell the device for clinical applications such as intraoperative brain mapping. CEO Michael Mager said the company went from idea to FDA clearance in four years since its founding.

In October 2025, Precision published a paper in the journal Nature Biomedical Engineering covering the experiences of its first human patients. In the clinical pilot, the Layer 7 system detected brainwave patterns generated when patients attempted to speak with roughly 80 percent accuracy. This was achieved with only four minutes of training data and 54 speech recordings. At the time of publication, Precision reported it had implanted Layer 7 in more than 50 patients and was conducting long-term studies at six major medical institutions across the United States.

Precision's strategy follows the orthodox path of medical device development rather than Silicon Valley's speed race. They designed the system so hospitals can use the facilities and equipment they already have. No need to buy an expensive surgical robot, no need for neurosurgeons to spend months learning a new procedure. That is Rapoport's philosophy: the best technology is technology that blends naturally into the environment that already exists.

Layer 7's significance in the market lies in breaking the simple dichotomy of invasive versus non-invasive. Invasive systems offer good signals but carry a heavy surgical burden. Non-invasive systems are safe but limited in bandwidth. Precision opened a new point between the two. Rapoport called it the Goldilocks solution. Not too hot, not too cold, just the right temperature. Far more powerful than non-invasive methods, yet far safer than fully invasive ones; an optimal balance.

Questions remain, of course. Can signals read from the brain's surface ever be as rich as those read directly from inside it? Instead of hearing individual neuron spikes, you are hearing the chorus of thousands of neurons. Is that enough for precise decoding? Precision believes it is. But the proof is still in progress. The current 30-day approval window is not the finish line; it is the first step. The bold adventure of piercing the brain versus the cautious approach of covering it. This clash of philosophies will be a critical fork in deciding which direction the future of BCI takes.

C. Paradromics: The High-Bandwidth Connexus and the FDA

Under the scorching Texas sun in Austin, CEO Matt Angle and his team at Paradromics have been quietly preparing a weighty challenge. The company's motto is straightforward: bandwidth is power. If the BCI industry is competing over internet speeds, Paradromics has declared it will lay the fiber optic cable.

The human brain generates an enormous volume of data every second. When we decide to say a single word, tens of thousands of neurons in the motor cortex fire in precise patterns. These are commands dictating how to move the lips, where to place the tongue, and how to vibrate the vocal cords. If conventional BCIs were sipping from this flood of information through a straw, Paradromics aims to hook up a fire hose.

Their Connexus BCI is the embodiment of that philosophy. More than 400 platinum-iridium electrodes are implanted just beneath the surface of the cerebral cortex. Each electrode is thinner than a human hair. These electrodes directly measure the action potentials, or spikes, of individual neurons. Unlike Neuralink's flexible polymer threads, Paradromics chose platinum-iridium, a material proven over decades in medical devices. CEO Angle argues that surviving the harsh environment inside the brain over the long term demands a material with a proven track record.

The Connexus architecture is distinctive. A cortical module implanted in the brain, a cranial hub that processes signals inside the skull, and a transceiver implanted in the chest that wirelessly transmits data to the outside world form a single integrated system. Signals from the brain travel to the chest receiver, which then wirelessly relays them through the skin to an external computer. The entire process happens in milliseconds.

The first application Paradromics is pursuing is speech restoration. Imagine patients who can neither speak nor write because of ALS or stroke. Their brains remain intensely active. They have sentences they want to say, emotions they want to convey. The signals simply never reach their lips and tongue. Paradromics is building a bypass to replace that broken bridge, reading the intention to speak from the brain and converting it into text or synthesized voice.

Natural human conversation runs at roughly 150 words per minute. Communication speeds achieved by existing BCIs fall far short of that mark. Moving a cursor to select letters one at a time is painfully slow. Eye-tracking systems are just as frustrating. Paradromics is targeting an information transfer rate above 200 bits per second. That figure exceeds any BCI in existence today. The goal goes beyond individual characters or words, aiming for complex output approaching continuous speech.

On the regulatory front, Paradromics has reached an important milestone. The company received FDA Breakthrough Device designation twice.

The first was for restoring communication in patients who have lost the ability to speak.

The second was for restoring computer control in patients with severe motor function loss.

Breakthrough Device designation is not approval. It does mean, however, that the FDA recognized the technology's potential to be a breakthrough in treating life-threatening or irreversible conditions. It grants the company close FDA support throughout development and review.

In June 2025, Paradromics successfully completed its First-in-Human Recording. A team led by neurosurgeon Dr. Matthew Willsey at the University of Michigan temporarily inserted the Connexus during epilepsy surgery and captured high-resolution neural signals. The device was safely implanted in under 20 minutes, completed its recording, and was removed without damage. CEO Angle said: 'This procedure is a pivotal turning point for Paradromics. We are now a clinical-stage company.'

Then in November 2025, Paradromics announced that it had received FDA IDE (Investigational Device Exemption) approval and would begin its Connect-One early feasibility clinical trial. The company

became the first to receive IDE approval for speech restoration using a fully implantable BCI. The trial will begin in the first quarter of 2026 with two patients. Participants will be recruited from three clinical sites: UC Davis, Massachusetts General Hospital, and the University of Michigan. They are individuals whose severe motor impairment has left them with critically limited speech and limb movement.

CEO Angle's confidence is striking. He does not hesitate to publicly criticize the limitations of Neuralink's device. In October 2025, he posted a lengthy blog article titled 'Neuralink Device Limitations.' He declared that in the first quarter of 2026, they would begin clinical trials with a brain-computer interface built on the world's best engineering. 'This is the device patients deserve.'

The road ahead is not all rosy, of course. Paradromics' approach is highly invasive. Inserting electrodes deep into brain tissue carries the burden of surgery, device durability concerns, and the risk of tissue reaction. Heat is another problem. High-performance chips inevitably generate heat, and the brain is an organ sensitive to temperature changes. Without solving this issue, long-term use is impossible.

Paradromics' bet will be decided the moment high bandwidth translates into real clinical benefit. Can a patient speak faster and with less fatigue? Can error rates drop low enough for everyday use? Can the results be proven as medical value, meaning the restoration of autonomy in daily life? Breakthrough Device designation and IDE approval mean the company has stepped into the ring to make that proof. In an era where data is power, their strategy of extracting the most brain data at the highest fidelity cuts straight through the heart of the BCI competition.

D. Kernel: A Non-Invasive fNIRS Helmet Takes on the Consumer Market

Silicon Valley billionaire Bryan Johnson is known for being an eccentric figure. He invests millions of dollars each year trying to reverse his biological age to 18. He swallows dozens of supplements daily and measures every piece of biometric data about himself each night. This anti-aging project, called Blueprint, has made him the tech world's most extreme biohacker. In 2016, he put more than $50 million of his own money into founding a company called Kernel.

Johnson's question was straightforward. Why do we measure our heart rate and blood sugar every day but never measure the brain, the very core of who we are? Smartwatches tell us our step count and sleep patterns. They don't tell us that depression is setting in, that cognitive function is declining, or that focus is slipping away. The future Kernel envisions is a world with a thermometer for the mind, one that tracks the health of the brain.

Kernel walks a completely different path from the three companies discussed earlier. No opening the skull. No surgical robots. No sterile operating rooms. What they built is a helmet. This device, which looks like a bicycle helmet or a futuristic headset, is called Kernel Flow, and it stands at the forefront of non-invasive BCI.

Kernel Flow uses a technology called time-domain functional near-infrared spectroscopy (TD-fNIRS). Here is how it works. The helmet fires near-infrared laser pulses into the brain, each pulse lasting less than 150 picoseconds. The light passes through the scalp and skull, reaches the brain's surface, and bounces back. By analyzing how long the light takes to return and how much was absorbed, the system can detect changes in blood oxygen levels within the brain's vessels. When a region of the brain becomes active, oxygen-rich blood rushes to that area. Kernel Flow picks up these subtle shifts and maps brain activity. It reads the mind through blood flow, not electrical signals.

The Kernel Flow helmet weighs about two kilograms. Fifty-two modules arranged across both sides of the head contain integrated laser sources and photodetectors. Each module holds one laser source and six detectors in a hexagonal array. The full system provides more than 3,500 measurement channels, covering the entire brain. It can monitor brain activity at a sampling rate of over 200 times per second.

Conventional TD-fNIRS equipment was large enough to fill an entire room. It cost billions of won (millions of dollars). Patients had to sit motionless in a hospital for measurements to be taken. Kernel's breakthrough was shrinking that room-sized laboratory apparatus down to something you can wear on your head and taking it outside the lab. According to a study published in the Journal of Biomedical Optics in 2022, Kernel Flow

maintained performance comparable to existing benchtop TD-fNIRS systems while achieving portability.

The limitations, of course, are clear. Signals measured with light from outside the skull have far lower resolution than those captured by electrodes implanted inside the brain. Individual neuron activity is invisible. Precisely controlling a robotic arm with thought alone remains beyond this technology's current reach. Near-infrared light is also absorbed at different rates depending on hair type and skin pigmentation. Ensuring accurate measurements across diverse hair and skin types is still an unsolved challenge.

So what is Kernel after? The market they are targeting differs from the traditional medical BCI space. One axis is clinical research. Non-invasively tracking the treatment progress of depression patients and quantitatively measuring a drug's effect on the brain. The FDA has approved studies using Kernel Flow to measure how psychiatric medications like ketamine affect the brain. If a pharmaceutical clinical trial can show a drug's effect through objective metrics, it could dramatically cut development costs and timelines.

The other axis is the consumer market. Visualizing the effects of meditation in real time, confirming the results of focus training with hard numbers, and detecting early signs of cognitive decline before they progress. Just as a smartwatch shows your heart rate, Kernel wants to become a wearable that shows your brain's activity level. Reality, though, is still far off. The Kernel Flow system is listed at $117,200 on Kernel's developer page. Tax and shipping are extra. That single number shuts the consumer market door for now. Kernel is not targeting a market where ordinary people buy helmets today. Their strategy is a detour: standardize the hardware, collect large-scale data, build brain-based biomarkers from that data, and once clinical usefulness is proven, bring a lighter and cheaper version down to the general public.

Kernel Flow 2, launched in 2023, took a step beyond its predecessor. By integrating EEG (electroencephalography) with TD-fNIRS, it can now measure blood flow changes and electrical signals simultaneously. A user-friendly interface, automated quality reports, and real-time data processing were also added. The device is evolving beyond a research tool, optimized now for clinical research.

Kernel's challenge goes beyond technology. It is cultural. The aim is not to hack or manipulate the brain but to measure and understand it so that people can improve themselves. Bryan Johnson puts it this way: 'We look in the mirror to know ourselves. But a mirror only shows the surface. Kernel will be the mirror for what's inside.'

A BCI revolution that happens on a living room sofa, not on an operating table. Kernel is knocking on the door of the posthuman era through the safest, most accessible method possible. Whether that door will open, and if so when, remains unknown. One thing, though, is clear. Where Neuralink, Synchron, Blackrock, Precision, and Paradromics are building medical devices for people with severe disabilities, Kernel is experimenting with an entirely new layer of the neurotech ecosystem, one that extends to the brains of healthy individuals. A world in which anyone can peer inside their own brain. Whether that turns out to be a blessing or a catastrophe depends on how we choose to use it.